Universidade Federal Fluminense
uff.brTotal trials
71
Active
20
Phase 3
2
Total enrollment
4,996
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ferrous sulfate 3 days week | — | — | — | — | — | 1 | |
| Ferrous sulfate daily | — | — | — | — | — | 1 | |
| Ferrous sulfate higher concentration | — | — | — | — | — | 1 |
Next readouts
- 2026-12-29
Top conditions
- Inflammation13
- Chronic Kidney Diseases11
- Oxidative Stress8
- Chronic Kidney Disease5
- Dental Restoration Failure of Marginal Integrity5
- Hemodialysis4
- Hypertension3
- Diabetes3
Frequently asked questions about Universidade Federal Fluminense
- How many clinical trials does Universidade Federal Fluminense have on ClinicalTrials.gov?
- Universidade Federal Fluminense is listed as the lead sponsor on 71 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidade Federal Fluminense's trials are in Phase 3?
- 2 of Universidade Federal Fluminense's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Universidade Federal Fluminense focus on?
- Universidade Federal Fluminense's most-studied conditions on ClinicalTrials.gov are Inflammation, Chronic Kidney Diseases, Oxidative Stress, Chronic Kidney Disease, Dental Restoration Failure of Marginal Integrity.
- When are Universidade Federal Fluminense's next clinical trial readouts?
- Universidade Federal Fluminense has 1 upcoming primary-completion readout tracked here; the soonest is “Oral Iron Supplementation for Patients With Chronic Kidney Disease”, expected around 2026-12-29.